Joaquin Vega Gonzales-Portillo

Dr. Joaquin Vega Gonzales-Portillo

Student
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MAMauricio Muleiro Alvarez
Mauricio Muleiro Alvarez
Gabriela Cano HerreraGabriela Cano Herrera
Gabriela Cano Herrera
MMMaria Fernanda Osorio Martinez
Maria Fernanda Osorio Martinez
JGJoaquin Vega Gonzales-Portillo
Joaquin Vega Gonzales-Portillo
GMGerman Rivera Monroy
German Rivera Monroy
Antonio IbarraAntonio Ibarra
Antonio Ibarra
Parkinson’s disease (PD) is a gradually worsening neurodegenerative disorder affecting the nervous system, marked by a slow progression and varied symptoms. It is the second most common neurodegenerative disease, affecting over six million people in the world. Its multifactorial etiology includes environmental, genomic, and epigenetic factors. Clinical symptoms consist of non-motor and motor symptoms, with motor symptoms being the classic presentation. Therapeutic approaches encompass pharmacological, non-pharmacological, and surgical interventions. Traditional pharmacological treatment consists of administering drugs (MAOIs, DA, and levodopa), while emerging evidence explores the potential of antidiabetic agents for neuroprotection and gene therapy for attenuating parkinsonian symptoms. Non-pharmacological treatments, such as exercise, a calcium-rich diet, and adequate vitamin D supplementation, aim to slow disease progression and prevent complications. For those patients who have medically induced side effects and/or refractory symptoms, surgery is a therapeutic option. Deep brain stimulation is the primary surgical option, associated with motor symptom improvement. Levodopa/carbidopa intestinal gel infusion through percutaneous endoscopic gastrojejunostomy and a portable infusion pump succeeded in reducing “off” time, where non-motor and motor symptoms occur, and increasing “on” time. This article aims to address the general aspects of PD and to provide a comparative comprehensive review of the conventional and the latest therapeutic advancements and emerging treatments for PD. Nevertheless, further studies are required to optimize treatment and provide suitable alternatives.

6 September 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
RBReed Berlet
Reed Berlet
SAStefan Anthony
Stefan Anthony
BBBeverly Brooks
Beverly Brooks
ZWZhen-jie Wang
Zhen-jie Wang
NSNadia Sadanandan
Nadia Sadanandan
Cesar BorlonganCesar Borlongan
Cesar Borlongan
Stem cell transplantation with rehabilitation therapy presents an effective stroke treatment. Here, we discuss current breakthroughs in stem cell research along with rehabilitation strategies that may have a synergistic outcome when combined together after stroke. Indeed, stem cell transplantation offers a promising new approach and may add to current rehabilitation therapies. By reviewing the pathophysiology of stroke and the mechanisms by which stem cells and rehabilitation attenuate this inflammatory process, we hypothesize that a combined therapy will provide better functional outcomes for patients. Using current preclinical data, we explore the prominent types of stem cells, the existing theories for stem cell repair, rehabilitation treatments inside the brain, rehabilitation modalities outside the brain, and evidence pertaining to the benefits of combined therapy. In this review article, we assess the advantages and disadvantages of using stem cell transplantation with rehabilitation to mitigate the devastating effects of stroke.

17 March 2022 in Cells
Verified
Journal Article
Open access
PDF file
BBBeverly Brooks
Beverly Brooks
DEDominique Ebedes
Dominique Ebedes
AUAhsan Usmani
Ahsan Usmani
JGJoaquin Vega Gonzales-Portillo
Joaquin Vega Gonzales-Portillo
DGDaniel Gonzales-Portillo
Daniel Gonzales-Portillo
Cesar BorlonganCesar Borlongan
Cesar Borlongan
Ischemic brain injury represents a major cause of death worldwide with limited treatment options with a narrow therapeutic window. Accordingly, novel treatments that extend the treatment from the early neuroprotective stage to the late regenerative phase may accommodate a much larger number of stroke patients. To this end, stem cell-based regenerative therapies may address this unmet clinical need. Several stem cell therapies have been tested as potentially exhibiting the capacity to regenerate the stroke brain. Based on the long track record and safety profile of transplantable stem cells for hematologic diseases, bone marrow-derived mesenchymal stromal cells or mesenchymal stromal cells have been widely tested in stroke animal models and have reached clinical trials. However, despite the translational promise of MSCs, probing cell function remains to be fully elucidated. Recognizing the multi-pronged cell death and survival processes that accompany stroke, here we review the literature on MSC definition, characterization, and mechanism of action in an effort to gain a better understanding towards optimizing its applications and functional outcomes in stroke.

26 July 2024 in Arquivos Brasileiros de Neurocirurgia: Brazilian Neurosurgery
Verified
Journal Article
Open access
PDF file
JGJoaquin Vega Gonzales-Portillo
Joaquin Vega Gonzales-Portillo
MSMarco Gonzales-Portillo Showing
Marco Gonzales-Portillo Showing
LTLuis A. Huamán Tanta
Luis A. Huamán Tanta
SZSandro Casavilca Zambrano
Sandro Casavilca Zambrano
Introduction The present study describes a case of an intracranial solitary fibrous tumor (iSFT) concurrent with meningioma in different anatomical regions. Case Description A female patient, 64-years-old, presented with an 18-month history of progressive vision impairment in the right eye and no other neurological symptoms. The magnetic resonance imaging (MRI) revealed two solid and expansive lesions: one with right interhemispheric occipital location and dependent on the falx cerebri, and another located in the anterior skull base. We opted for a right frontotemporal craniotomy for the first tumor, and a right occipital craniotomy, 41-days later, for the second one, showing no postoperative complications. Histological and immunohistochemical findings confirmed the diagnosis of a grade-I fibrous meningioma and a grade-III SFT. After 9 months of follow-up, the patient showed vision improvement and no signs of neurological compromise or tumor recurrence in the last MRI. Conclusions The present study describes the first reported case of a patient with an intracranial SFT associated with a meningioma in different anatomical locations. The involved pathogenesis and evolution of both coexisting tumors are still unknown, which highlights the need for more case reports on them.